Ethical and public policy challenges for pharmacogenomics

Dialogues in Clinical Neuroscience

Volumn 16, Issue 4, 2014, Pages 567-574

  Gershon, Elliot S ^a   Alliey Rodriguez, Ney ^a   Grennan, Kay ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Ethics; Genetics; Mental disorder; Molecular network; Pharmacogenomics; Population genetics; Public policy

Indexed keywords

ARTICLE; ETHICS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC DISORDER; GENETIC SCREENING; GENETIC VARIABILITY; HEALTH CARE DELIVERY; HUMAN; INFORMED CONSENT; PERSONALIZED MEDICINE; PHARMACOGENOMICS; POLICY; PUBLIC HEALTH; LEGISLATION AND JURISPRUDENCE; PHARMACOGENETICS;

HUMANS; PHARMACOGENETICS; PUBLIC POLICY;

EID: 84925335327     PISSN: 12948322     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Conrado DJ, Rogers HL, Zineh I, Pacanowski MA. Consistency of drugdrug and gene-drug interaction information in US FDA-approved drug labels. Pharmacogenomics. 2013;14:215-223.
2. US Food and Drug Administration. Table of pharmacogenomic biomarkers in grug labeling. Available at: http://www.fda.gov/drugs/scienceresearch/ researchareas/pharmacogenetics/ucm083378.htm. Accessed October 2014.
3. Hicks JK, Swen JJ, Thorn CF, et al. Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharm Ther. 2013;93:402-408.
4. Wertz DC. Ethical, social and legal issues in pharmacogenomics. Pharmacogenomics J. 2003;3:194-196.
5. Biological insights from 108 schizophrenia-associated genetic loci. Nature. 2014;511:421-427.
6. Lee SH, Ripke S, Neale BM, et al. Genetic relationship between five psychiatric disorders estimated from genome-wide SNPs. Nat Genet. 2013;45:984-994.
7. International Schizophrenia Consortium: Purcell SM, Wray NR, Stone JR, et al. Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature. 2009;460:748-752.
8. Cross-Disorder Group of the Psychiatric Genomics C. Identification of risk loci with shared effects on five major psychiatric disorders:a genomewide analysis. Lancet. 2013:381:1371-1379
9. Gamazon ER, Badner JA, Cheng L, et al. Enrichment of cis-regulatory gene expression SNPs and methylation quantitative trait loci among bipolar disorder susceptibility variants. Mol Psychiatry. 2013;18:340-346.
10. Ji Y, Biernacka JM, Hebbring S, et al. Pharmacogenomics of selective serotonin reuptake inhibitor treatment for major depressive disorder:genome-wide associations and functional genomics. Pharmacogenomics J. 2013;13:456-463.
11. Gershon ES, Grennan K, Busnello J, et al. A rare mutation of CACNA1C in a patient with bipolar disorder, and decreased gene expression associated with a bipolar-associated common SNP of CACNA1C in brain. Mol Psychiatry. 2013;19:890-894.
12. Ferreira MA, O'Donovan MC, Meng YA, et al. Collaborative genomewide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet. 2008;40:1056-1058.
13. Levy NA, Janicak PG. Calcium channel antagonists for the treatment of bipolar disorder. Bipolar Disord. 2000;2:108-119.
14. Akpudo HA, Aleksic BG, Alkelai AH, et al. Summaries of oral sessions at the XXI World Congress of Psychiatric Genetics, Boston, Massachusetts, 17-21 October 2013: state of the field. Psychiatr Genet. 2014;24:125-150.
15. Malhotra D, McCarthy S, Michaelson JJ, et al. High frequencies of de novo CNVs in bipolar disorder and schizophrenia. Neuron. 2011;72:951-963.
16. Nurnberger JI, Jr., Koller DL, Jung J, et al. Identification of pathways for bipolar disorder: a meta-analysis. JAMA Psychiatry. 2014;71:657-64.
17. Fromer M, Pocklington AJ, Kavanagh DH, et al. De novo mutations in schizophrenia implicate synaptic networks. Nature. 2014;506:179-184.
18. Grennan KS, Chen C, Gershon ES, Liu C. Molecular network analysis enhances understanding of the biology of mental disorders. BioEssays. 2014;36:606-616.
19. Iancu OD, Darakjian P, Malmanger B, Walter NA, McWeeney S, Hitzemann R. Gene networks and haloperidol-induced catalepsy. Genes Brain Behav. 2012;11:29-37.
20. Korostynski M, Piechota M, Dzbek J, et al. Novel drug-regulated transcriptional networks in brain reveal pharmacological properties of psychotropic drugs. BMC Genomics. 2013;14:606.
21. Miguez DG. Network nonlinearities in drug treatment. Interdiscip Sci. 2013;5:85-94.
22. Rosenfeld S. Biomolecular self-defense and futility of high-specificity therapeutic targeting. Gene Regul Syst Bio. 2011;5:89-104.
23. Richelson E. Multi-modality:a new approach for the treatment of major depressive disorder. Int J Neuropsychopharmacol. 2013:1-10.
24. Dobrin R, Zhu J, Molony C, et al. Multi-tissue coexpression networks reveal unexpected subnetworks associated with disease. Genome Biol 2009;10:R55.
25. Lopes TJ, Schaefer M, Shoemaker J, et al. Tissue-specific subnetworks and characteristics of publicly available human protein interaction databases. Bioinformatics. 2011;27:2414-2421.
26. Zhang B, Horvath S. A general framework for weighted gene co-expression network analysis. Stat Appl Genet Mol Biol. 2005;4:Article17.
27. Cai C, Langfelder P, Fuller TF, et al. Is human blood a good surrogate for brain tissue in transcriptional studies? BMC Genomics. 2010;11:589.
28. Fuller TF, Ghazalpour A, Aten JE, Drake TA, Lusis AJ, Horvath S. Weighted gene coexpression network analysis strategies applied to mouse weight. Mamm Genome. 2007;18:463-472.
29. Kang HJ, Kawasawa YI, Cheng F, et al. Spatio-temporal transcriptome of the human brain. Nature. 2011;478:483-489.
30. Torkamani A, Dean B, Schork NJ, Thomas EA. Coexpression network analysis of neural tissue reveals perturbations in developmental processes in schizophrenia. Genome Res. 2010;20:403-412.
31. Chen C, Cheng L, Grennan K, et al. Two gene co-expression modules differentiate psychotics and controls. Mol Psychiatry. 2013;18:1308-1314.
32. Choi DW. Calcium and excitotoxic neuronal injury. Ann N Y Acad Sci. 1994;747:162-171.
33. Shao L, Vawter MP. Shared gene expression alterations in schizophrenia and bipolar disorder. Biol Psychiatry. 2008;64:89-97.
34. Barash CI. Ethical Issues in Pharmacogenetics. Action Bioscience; 2013. Available at: http://www.actionbioscience.org/biotechnology/ethical_ issues_in_pharmacogenetics.html. Accessed October 2014.
35. Gershon ES, Alliey-Rodriguez N. New ethical issues for genetic counseling in common mental disorders. Am J Psychiatry. 2013;170:968-976.
36. Wernig M, Zhao JP, Pruszak J, et al. Neurons derived from reprogrammed fibroblasts functionally integrate into the fetal brain and improve symptoms of rats with Parkinson's disease. Proc Natl Acad Sci U S A. 2008;105:5856-5861.
37. Tutton R. Pharmacogenomic biomarkers in drug labels:what do they tell us? Pharmacogenomics. 2014;15:297-304.